Does REGORAFENIB Cause Malignant neoplasm progression? 145 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 145 reports of Malignant neoplasm progression have been filed in association with REGORAFENIB (Stivarga). This represents 1.5% of all adverse event reports for REGORAFENIB.
145
Reports of Malignant neoplasm progression with REGORAFENIB
1.5%
of all REGORAFENIB reports
45
Deaths
16
Hospitalizations
How Dangerous Is Malignant neoplasm progression From REGORAFENIB?
Of the 145 reports, 45 (31.0%) resulted in death, 16 (11.0%) required hospitalization, and 2 (1.4%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REGORAFENIB. However, 145 reports have been filed with the FAERS database.
What Other Side Effects Does REGORAFENIB Cause?
Off label use (1,906)
Fatigue (1,530)
Palmar-plantar erythrodysaesthesia syndrome (1,230)
Diarrhoea (1,221)
Decreased appetite (941)
Asthenia (825)
Death (813)
Dysphonia (702)
Nausea (688)
Pain in extremity (686)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which REGORAFENIB Alternatives Have Lower Malignant neoplasm progression Risk?
REGORAFENIB vs REGORAFENIB\REGORAFENIB
REGORAFENIB vs RELATLIMAB
REGORAFENIB vs RELPAX
REGORAFENIB vs RELUGOLIX
REGORAFENIB vs REMDESIVIR